ArticleOpen veterinary journal2025
Investigation of augmentin-induced hepatobiliary damage and its modulation by N-acetylcysteine in male rats.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Augmentin is a common antibiotic used to treat infections. However, it may cause liver damage. Toxicity often involves oxidative stress and inflammation. N-acetylcysteine (NAC) is known for its antioxidant and anti-inflammatory effects and may help protect the liver. Aim: This study aimed to assess whether NAC could reduce Augmentin-induced liver and bile duct injury. Methods: Forty adult male rats were divided into four groups (T1, T2, T3, and T4). Group 1 was the control group. Group 2 received Augmentin (30 mg/kg/day). Group 3 received 150 mg/kg/day NAC. Group 4 received both NAC and Augmentin. Treatments lasted for 35 days. Serum levels of tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA), glutathione (GSH), and CYP7A1 were measured. Histopathology was also performed. Results: Augmentin alone caused a significant ( Conclusion: NAC reduced the oxidative stress and inflammation caused by Augmentin. It also protected the liver structure. These findings suggest that NAC is a useful supplement for preventing drug-induced liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.